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CPIC Updates
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines are published in full on the PharmGKB website (www.pharmgkb.org). Relevant information will be periodically reviewed and updated guidelines will be published online.
Focused Literature Review
A literature search of the PubMed (1966 to January 2013) and Ovid MEDLINE (1950 to January 2013) database using the keywords ((IL28B OR interleukin 28) AND (peginterferon OR pegylated-interferon alfa OR PEG/IFN) AND genotype) was performed. Only articles available in English were reviewed.
Other genes affecting PEG-interferon response
Many studies over the last three decades have evaluated genetic predictors of Hepatitis C virus (HCV) treatment response. Although the IFNL3 genotype has emerged as the strongest predictor of treatment response, a recent systematic review found that more than forty genes have been associated with treatment response or treatment-related adverse events (1). The review did not attempt to validate the individual studies suggesting associations but was meant to provide awareness of the research. Other than the IFNL3 genotype, these studies have not reported a consistent genetic association with HCV treatment response. Gene Ontology analysis categorized these genes into major groups of genes associated with the immune response, the inflammatory response, and the response to the virus (Table S1 ).
Available Genetic Test Options
Commercially available genetic testing options change over time. An updated and fully linked table is available at http://www.pharmgkb.org/gene/PA134952671#tabview=tab0&subtab=34. Furthermore, the Genetic Testing Registry (GTR) provides a central location for voluntary submission of genetic test information by providers and is available at http://www.ncbi.nlm.nih.gov/gtr/. However, at the time of the writing of this manuscript no genetic test information was available on the GTR website for IFNL3.
Levels of Evidence linking genotype to phenotype
The evidence summarized in Supplemental Table S4 has been graded using the three tiered system required by the Clinical Pharmacogenetics Implementation Consortium:
High: Evidence includes consistent results from well-designed, well conducted studies.
Moderate: Evidence is sufficient to determine effects, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies, generalizability to routine practice, or indirect nature of the evidence.
Weak: Evidence is insufficient to assess the effects on health outcomes because of limited number or power of studies, important flaws in their design or conduct, gaps in the chain of evidence, or lack of information.
Every effort was made to present evidence from high-quality studies, which provided the framework for the strength of therapeutic recommendations in Table 2 .
Strength of Recommendations
Overall, the dosing recommendations are simplified to allow rapid interpretation by clinicians.
We chose to use a slight modification of a transparent and simple system for just three categories for recommendations adopted from the rating scale for evidence-based recommendations on the use of retroviral agents (http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf): strong, where "the evidence is high quality and the desirable effects clearly outweigh the undesirable effects"; moderate, in which "there is a close or uncertain balance" as to whether the evidence is high quality and the desirable clearly outweigh the undesirable effects; and optional, in which the desirable effects are closely balanced with undesirable effects and there is room for differences in opinion as to the need for the recommended course of action.
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